Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region

Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures. This is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPaLM) regimens.

It is also worth noting that there is increasing evidence of the significance of TB lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Tuberculosis, Multi Drug Resistant Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Central Africa Gram-Positive Bacterial Infections Infections Molecular Epidemiology Multi Drug Resistant Tuberculosis Mycobacterium Infections Sprains and Strains Strains Tuberculosis Tuberculosis, Multidrug-Resistant Wounds and Injuries

Age range

9 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All GeneXpert positive TB patients and participants who provide written informed consent will be screened for the study. Participants aged above 8 who can provide sputum will also be screened.
Patients enrolled in the tuberculosis epidemiology (TB-EPI) study and eligible for MESTCAR will be enrolled without any additional consent form as the data to be collected for the two studies will be shared and no additional process is needed.

Exclusion criteria

Samples which do not meet the quality criteria.

Samples not enough to perform all of the laboratory process
Samples contaminated

Treatment and study plan

Primary outcomes

Proportion of drug-resistant strains with characterised resistance mutations

Time frame: 6 months
Proportion of strains with new/undefined mutations among those with unexplained phenotypic resistance

Time frame: 6 months
Proportion of cases demonstrating transmission links, overall and between countries

Time frame: 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jabar Babatunde Pacome AGBO ACHIMI ABDUL

CONTACT

[email protected]

+24177469843

Rick elsy mirna NNOH DANSOU AKOUA

CONTACT

[email protected]

+241 74474314

Sponsors and collaborators

Lead sponsor

Centre de Recherche Médicale de Lambaréné

Other

Collaborators

Centre Pasteur du Cameroun
Fondation Congolaise pour la Recherche Médicale
GlaxoSmithKline

Registry information

Acronym: MESTCAR

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2026
First posted: Jun 12, 2025
Registry last updated: Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting